In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
Blockbuster JAKAFI's revenue-driving indications are Myelofibrosis, Polycythemia Vera, and GvHD. JAKAFI's year-on-year cost increase of more than 5% since 2020 (ICER reports) is one factor driving its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback